Sign in

Fatty liver disease (MASLD/MASH)

Current status: Treatable, not yet curable

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

Read more about fatty liver disease (MASLD/MASH)
Where research stands todayUpdated 15 Nov 2026

Trial-stage treatments and research studies you can join

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsSpain, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with cirrhosis caused by fatty liver disease

    Tests efruxifermin against a placebo in adults with cirrhosis from MASH.

    Barcelona, SpainAlso Madrid, Majadahonda, Sabadell, Santander, Seville, ValenciaAge 18 to 80
  2. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver scarring from fatty liver disease

    Tests survodutide, a weekly injection, in adults with MASH cirrhosis.

    A Coruña, SpainAlso Barcelona, Córdoba, Madrid, Majadahonda, PontevedraAge 18+
  3. Trial-stage treatmentPhase 3Soon in Spain
    Survodutide and heart structure and function in people with obesity and fatty liver disease

    Tests survodutide against placebo on heart health in adults with overweight and fatty liver.

    Barcelona, SpainAlso El Palmar, Madrid, Sanlúcar de Barrameda, ValenciaAge 18+
  4. Trial-stage treatmentPhase 2Soon in Spain
    Testing ALN-CIDEB for fatty liver disease with liver scarring in adults

    Tests the study drug ALN-CIDEB against placebo in adults with liver scarring from MASH.

    Barcelona, SpainAlso Madrid, Pontevedra, Sabadell, Santander, Valencia, ZaragozaAge 18 to 75
  5. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with liver scarring from fatty liver disease

    Tests efruxifermin against a placebo in adults with fatty liver disease and mild liver scarring.

    Barcelona, SpainAlso Madrid, Majadahonda, Sabadell, Santander, Seville, ValenciaAge 18 to 80
  6. Trial-stage treatmentPhase 3Taking people
    Tests survodutide in adults with liver disease and moderate or advanced liver fibrosis

    Tests survodutide weekly injections against placebo in adults with fatty liver disease and scarring.

    A Coruña, SpainAlso Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, ZaragozaAge 18+
  7. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin against placebo in liver scarring from fatty liver disease

    Tests pegozafermin doses versus placebo in adults with MASH and liver scarring.

    Badalona, SpainAlso Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de CompostelaAge 18 to 80
  8. Trial-stage treatmentPhase 3Taking people
    Tests pegozafermin in adults with liver scarring from fatty liver disease

    Tests pegozafermin against placebo in adults with compensated cirrhosis from MASH.

    Almería, SpainAlso Badalona, Barcelona, Córdoba, Madrid, Pontevedra, Santander, Santiago de Compostela, ZaragozaAge 18 to 75
  9. Trial-stage treatmentPhase 3Taking people
    Tests retatrutide and tirzepatide in adults with fatty liver disease at high risk

    Tests retatrutide and tirzepatide in adults with fatty liver disease to prevent serious liver problems.

    A Coruña, SpainAlso Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra, Santander, …Age 18+
  10. Trial-stage treatmentPhase 3Taking people
    Tests efimosfermin alfa injection in adults with fatty liver scarring

    Tests efimosfermin alfa injection for safety in adults with MASH liver disease.

    A Coruña, SpainAlso Alcorcón, Barcelona, Córdoba, León, Madrid, Santander, Valencia, ValladolidAge 18 to 75
  11. Trial-stage treatmentPhase 4Soon in Spain
    Compares Weight-Loss Surgery and Medicines for Fatty Liver Scarring

    Compares metabolic surgery with incretin medicines in adults with liver scarring from fatty liver disease.

    Barcelona, SpainAge 18 to 75
  12. Trial-stage treatmentPhase 2Taking people
    Tests nicotinamide in adults with liver fibrosis and fatty liver disease

    Compares nicotinamide with a placebo in adults with liver scarring.

    Barcelona, SpainAge 18 to 85
  13. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with fatty liver disease and scarring

    Tests efruxifermin against placebo in adults with liver inflammation and fibrosis from MASH.

    Barcelona, SpainAlso Madrid, Majadahonda, Sabadell, Santander, ValenciaAge 18+
  14. Research studyTaking people
    How long adults with psoriasis and fatty liver disease stay on secukinumab

    Looks back at secukinumab use in adults with plaque psoriasis and fatty liver disease.

    Badalona, SpainAlso Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, ZaragozaAge 18 to 100
  15. Trial-stage treatmentTaking people
    Exercise Program for Fatty Liver Disease in Middle-Aged and Older Adults

    Tests a 12-week exercise program in adults with fatty liver disease.

    Madrid, SpainAge 40+
  16. Trial-stage treatmentPhase 3Taking people
    Tests efruxifermin in adults with scarred liver from fatty liver disease

    Tests efruxifermin against placebo in adults with cirrhosis from MASH liver disease.

    Barcelona, SpainAlso Madrid, Sabadell, Santander, ValenciaAge 18+
  17. Trial-stage treatmentPhase 3Soon in Spain
    Tests efimosfermin against placebo in adults with cirrhosis from MASH

    Tests efimosfermin versus placebo in adults with compensated cirrhosis from MASH.

    Alcorcón, SpainAlso Barcelona, Córdoba, León, Madrid, ValenciaAge 18+
  18. Trial-stage treatmentPhase 3Soon in Spain
    Tests efimosfermin against placebo in adults with cirrhosis caused by MASH

    Tests efimosfermin, compared with a placebo, in adults with MASH-related cirrhosis.

    Alcorcón, SpainAlso Barcelona, Córdoba, León, Madrid, ValenciaAge 18+
  19. Trial-stage treatmentSoon in Spain
    Butyrate or intensive lifestyle changes for fatty liver in adults with type 1 diabetes

    Tests butyrate, lifestyle changes, or both for fatty liver in adults with type 1 diabetes.

    Málaga, SpainAge 18 to 75
  20. Trial-stage treatmentTaking people
    Diet and exercise program for people with fatty liver disease linked to metabolism

    Tests a Mediterranean diet plus exercise program in adults with metabolic-related fatty liver disease.

    Seville, SpainAge 18+

Where treatment stands

These texts do not say it can be cured, but healthy lifestyle changes can reduce fat in the liver, help repair damage or stop it getting worse.

Recent EU-listed medicines are resmetirom (first EU approval August 2025) and semaglutide (March 2026), maybe first for another disease.

Approved: 2

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 18

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Words used here

Placebo: a dummy treatment without the medicine, used for comparison.

Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.

Where this comes from

The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.

A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.

The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.

Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 53 other open phase 2 trials are not listed.

Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for fatty liver disease (MASLD / MASH). AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.

Not medical advice. Talk to your doctor before you change any treatment.

The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.

Support organisations

Patient organisations and helplines in Spain, for you and your family.

Fatty liver disease (MASLD/MASH) organisations in Spain

  • Federacion Espanola del Higado (FEH, formerly FNETH)

    Liver patient federation: liver cancer and cholangiocarcinoma information, free psychological support, legal advice, accompaniment and temporary accommodation.

General support in Spain

  • Línea 024 de atención a la conducta suicida

    Spain's free 24/7 national helpline 024 of the Ministry of Health for people with suicidal thoughts and their relatives.

  • Teléfono de la Esperanza

    Spanish non-profit offering a free, confidential crisis and emotional support line and mental health promotion across Spain.

International organisations

Patient organisation umbrella bodies

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.No open programme yet
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

2 medicines are approved for fatty liver disease (MASLD/MASH) in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 11 Nov 2026 in the official lists of the US (FDA), the EU (EMA), Japan (PMDA, approvals since April 2004), Switzerland (Swissmedic), France (ANSM, medicines approved in France only) and Taiwan (TFDA). For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

“Cures” others already fact-checked

See all 4

About fatty liver disease (MASLD/MASH)

Sources: NHS, MedlinePlus

A common condition in which fat builds up in the liver, often linked to carrying extra weight. Most people have no signs, and it is often found by chance during tests for something else. Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage. It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.

What is it?

In this condition fat builds up in the liver. Its new name is MASLD (metabolic dysfunction-associated steatotic liver disease); it used to be called NAFLD. It is not caused by heavy drinking. There are four stages: fat alone (most people only have this and it does not usually cause problems); fat with inflammation (MASH, once called NASH); fibrosis (scarring); and cirrhosis, severe damage that affects how well the liver works.

It is very common: it is the most common long-term liver disease. It is more likely if you are overweight, especially around the waist, if you have type 2 diabetes, high blood pressure or high cholesterol, if you are not very active, or if you are over 50. Children can get it too. The exact cause is not known.

The first signs

Usually there are no signs, and it is often found during tests for something else.

  • feeling extremely tired;
  • feeling generally unwell;
  • discomfort or pain at the top right of the tummy, under the ribs.

How doctors find out

It is usually found after blood tests or scans done for another reason show signs of problems with your liver. Your family doctor asks about your symptoms and how much alcohol you drink, and measures your height, weight and waist. More blood tests and sometimes an ultrasound scan of your tummy can show the fat, rule out other causes and check for liver damage. If there is damage to your liver, you will need to see a liver specialist in hospital. Sometimes a biopsy is done to confirm the diagnosis and check for liver damage.

Current treatment

Lifestyle changes for everyone (healthy diet, at least 150 minutes of exercise a week, weight loss, little alcohol, no smoking), with pioglitazone or vitamin E from a specialist if there is scarring.

Will it get worse?

Most people only ever have the first stage, which usually causes no problems. A small number go on to inflammation and scarring, and some to cirrhosis, which can lead to bleeding inside the body, liver failure or liver cancer. It is also linked to heart disease, kidney disease, high blood pressure and type 2 diabetes. Healthy changes lower all these risks.

Medicines: what helps, and what to watch for

If there is scarring, a liver specialist may prescribe pioglitazone or vitamin E. For people with obesity, specialists may suggest weight-loss medicines. More research is needed to know which medicines are safe and work well.

Healthy changes help most

  • exercise for at least 150 minutes a week;
  • lose weight if you are overweight: it can reduce the fat, inflammation and scarring;

Weight-loss surgery or a transplant, for some people

For people with obesity, a specialist may recommend weight-loss surgery. In very severe cases, when the liver fails, a liver transplant may be needed.

Can it get better?

Healthy changes can reduce the fat in the liver and may repair damage or stop it getting worse. More studies are needed to see whether certain medicines are safe and work well to treat MASLD; studies are listed on ClinicalTrials.gov.

See the 425 trials you can join